




Revista de Psiquiatría y Salud Mental

www.elsevier.es/saludmental



SCIENTIFIC LETTER

Real clinical setting intravenous ketamine use for treatment resistant depression: 12 month follow-up after initial response



Uso de ketamina intravenosa para depresión resistente a tratamiento en un contexto clínico real: seguimiento de 12 meses tras respuesta inicial

Since 2008 many studies have reported short-term clinical improvement after acute ketamine administration; however, follow-up studies for more than 8 weeks are very limited or are focused on ketamine monotherapy¹ time until relapse varying widely between studies (16–168 days).^{2,3} Available information regarding treatment with ketamine raises a large number of questions⁴: (1) What can we expect from ketamine in a real clinical setting? (2) Can ketamine be an effective alternative treatment for patients not responding to ECT? (3) Are tolerance and dependence limiting its use? (4) What is the best maintenance treatment after initial response?

In our study, a compassionate and protocolized intravenous treatment schedule is prescribed in patients suffering from a Severe Major Depressive Episode (MADRS > 35) without therapeutic alternative after lack of response after bilateral ECT. All patients received a 0.5 mg/kg dose of ketamine in intravenous (i.v.) infusion for 40 min, two or three times per week until at least 6 sessions were completed. Clinical evolution was measured by using MADRS (Montgomery-Asberg Depression Rating Scale), FAST (Functional Assessment Staging Test) and CGI (Clinical Global Impression) scales.

10 patients with depression resistant to pharmacological treatment and ECT were treated with ketamine i.v. The sample includes 7 women and 3 men with a mean age of 61.5 years (SD: 13.84) and age range between 35 and 81 years (Table 1). Mean MADRS score prior to ketamine treatment was 45.50 (SD: 6.58). The mean value for CGI was 5.80 (SD: 0.92), with a mode of 6 (severely ill).

Acute intensive ketamine treatment response was assessed during hospitalization. An average of 7.4 (SD: 3.92) ketamine infusions were administered during the acute phase of treatment. The mean reduction of the MADRS scale after completing this phase was 25.2 points (SD: 10.09)

($p = 0.005$). The proportion of respondent patients was 40%. All patients exhibited at least partial response, although none reached remission. The CGI value decreased to 2.7 (SD: 1.337) ($p = 0.005$). 6 patients completed the follow-up, 3 of them (50%) continued in remission without requiring more ketamine infusions (Fig. 1). The 3 (50%) remaining patients required occasional ketamine infusions due to exacerbation of depressive symptoms; a total number of 10 or 11 infusions during the 1 year-follow-up period.

According to the FAST scale there was a significant improvement in overall functioning during the 12-month follow-up. In the specific items for cognitive functioning, the pre-treatment score was 12.33 points (SD: 12.33) and 3.33 (SD: 2.42) after the one year follow up.

Studies published to date describing the use of ketamine have some limitations: heterogeneous definition of TRMD,⁵ short duration, ethical conflicts regarding the use of placebo and methodological difficulties to include patients whose severity is close to that observed in clinical practice.^{5,6} Our case series of 10 patients with severe depression includes patients suffering from psychotic symptoms, bipolar depression, high suicide risk and a high degree of functional disability; these features would have excluded them from clinical trials.

Following acute and serial administration of ketamine, the MADRS score for our patients decreased significantly in most cases, replicating previous studies.^{1–3} In some cases, a reduction in the MADRS score was sustained for a number of weeks and two patients achieved maximum improvement or remission four or ten months after last administration. This might suggest a long-term action of ketamine. Furthermore, during the follow-up phase, a total number of four patients continued in clinical remission with pharmacological maintenance treatments (fundamentally lithium⁷ and tricyclic antidepressants⁸) without requiring new ketamine infusions.

The other half of the patients followed to 12 months required occasional infusions of ketamine due to depressive relapse symptoms; mean number of administrations was less than 1 for every month and the ketamine dose used was similar to acute phase (0.5 mg/kg). Our findings do not support the existence of tolerance or dependence phenomena, nor the need for continued serial administrations to sustain improvement.

In our series patients with depression-congruent psychotic symptoms achieved remission of symptomatology without requiring the use of antipsychotics and no manic

Table 1 Demographic and clinical description. Main outcomes.

	Psychiatric comorbidity ^b	Previous antidepressant ^c	ECT (<i>n</i> sessions)	Suicide	MADRS (baseline/1 month/12 month)	Functionality (FAST) (baseline/12 month) ^c	Medical comorbidity	Adverse event	AD strategy
PAC1: W57/MDR P ^a	NO	ISRS, TCA, V	YES (42)	Passive	51/19/29	60(13)/40 (6)	NO	Dissociative Sedation	Nortriptiline Lithium Lamotrigine
PAC2: W67/MDR P	NO	TCA, V, Li, Valp, M	YES (18)	Serious attempt	46/13/16	65 (15)/30 (5)	OSA Hypothyroid.	X	Nortriptiline Lithium
PAC3: W56/MD	NO	ISRS, Dul, V, Valp	YES (13)	Active plan	35/22/7	54(11)/23 (0)	NO	X	Nortriptiline Lithium
PAC4: M 59/BIP I	ED	TCA, MAO, Li	YES (10)	Passive	47/25/20	59(11)/32 (3)	NO	X	Imipramine Lithium
PAC5: W81/MDR P	Cognitive impairment	V, Dul, TCA, M	YES (4)	Passive	48/40/-	-	Hypercholest.	X	Zuclopenthiax.
PAC6: W 81/MDR	NO	V, ISRS	YES (3)	Passive	42/22/-	-	DM AF	Sedation	Venlafaxine Mirtazapine
PAC7: W 35/MD	BPD	V, Ago, ISRS	YES (5)	Active plan	47/20/-	-	Hypothyroid Raynaud Sd Asthma	Sedation	Venlafaxine Bupropion
PAC8: M56/BIP II	OCD	Lam, Li	YES (8)	NO	56/16/-	-	NO	X	Lithium Lamotrigine Mirtazapine
PAC 9: W56/MDR	NO	TCA, Bu, Li	YES (7)	NO	48/13/0	64(13)/14 (1)	Hypertension Lung Neopl Hypothiroid.	X	Nortriptiline Lithium Lamotrigine
PAC10: M70/MDR	NO	ISRS, V, TCA	YES (8)	NO	35/13/9	54(11)/35 (5)	DM HTA Hypercolest.	Dissociative	Nortriptiline Lithium Olanzapine

^a MDR: Recurrent major depressive disorder. MD: Major depression. P: Psychotic features. BIP: Bipolar disorder.^b ED: Eating disorder. BPD: Borderline personality disorder. OCD: Obsessive-compulsive disorder.^c V: Venlafaxine. Li: lithium. Valp: Valproate. M: mirtazapine. D: duloxetine. Ago: Agomelatine. Lam: Lamotrigine. Bu: Bupropion.




Figure 1 MADRS score during 1 year follow-up and ketamine infusions for each patient.

switch occurred in any of our patients (unipolar or bipolar depression).

In our series of 10 patients, ketamine improved the depressive symptomatology during the acute phase and also during one year follow-up. In that period, no patterns of abuse, tolerance or cognitive related side effects have been observed. Lithium and tricyclic antidepressants may provide a useful option toward the objective of consolidating clinical improvement and preventing new episodes.

References

1. Murrough JW, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. *Biol Psychiatry*. 2013;74:250–6.
2. Diamond PR, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. *J Psychopharmacol*. 2014, p. 026988114527361.
3. Shiroma PR, et al. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression. *J Affect Disord*. 2014;155:123–9.
4. Sanacora G, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. *JAMA Psychiatry*. 2017.
5. Thase ME, Rush AJ. When at first you don't succeed: sequential strategies for antidepressant nonresponders. *J Clin Psychiatry*. 1997.
6. Wan L-B, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. *J Clin Psychiatry*. 2014;76:247–52.
7. Chiu C-T, et al. The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress. *Int J Neuropsychopharmacol*. 2015, pyu102.
8. Kellner CH, et al. Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). *Arch Gen Psychiatry*. 2006;63:1337–44.

Nora Olazabal^{a,*}, Sonia Bustamante^a,
M. Aranzazu Madrazo^a, Luis Osa^a,
Ana M. O'Neill of Tyrone^a, Ana Catalán^{a,b},
Miguel Angel González-Torres^{a,b}

^a OSI Bilbao-Basurto. Hospital Basurto, Bilbao, Spain

^b Neuroscience Department, University of the Basque Country, Spain

* Corresponding author.

E-mail address: nora.olazabaleizaguirre@osakidetza.net (N. Olazabal).